Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABOSTO:EQL -2.66%40 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 40/100. The stock has 6 warning signs investors should review. Among 682 Drug Manufacturers companies, EQL Pharma AB ranks worse than 96.92% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. EQL Pharma AB's
Operating Income
for the
three
months ended in Jun. 2026 was kr-13.6 Mil. EQL Pharma AB's Interest Expense for the
three
months ended in Jun. 2026 was kr-7.5 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for EQL Pharma AB's Interest Coverage or its related term are showing as below:
OSTO:EQL'
s Interest Coverage Range Over the Past 10 Years
Min: 0.49 Med: 8.74 Max: 443.63
Current: 0.49
OSTO:EQL's Interest Coverage is ranked worse than 96.92% of 682
companies
in the Drug Manufacturers industry
Industry Median: 12.82
vs OSTO:EQL: 0.49
EQL Pharma AB (OSTO:EQL) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
EQL Pharma AB Interest Coverage Related Terms
EQL Pharma AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
EQL Pharma AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
EQL Pharma AB (OSTO:EQL) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on EQL Pharma AB and its competitors. Over the past decade, EQL Pharma AB's Interest Coverage has ranged from 0.49 to 443.63. According to the industry distribution chart, EQL Pharma AB ranks #661 out of 682 companies in the Drug Manufacturers industry, placing it in the top 96.9%.
Is EQL Pharma AB's Interest Coverage too high?
EQL Pharma AB's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 443.63. Based on the distribution chart, EQL Pharma AB ranks #661 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, EQL Pharma AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #661 out of 682 companies for Interest Coverage. This places EQL Pharma AB in the lower half of its industry. The industry median Interest Coverage is 12.82. Historically, EQL Pharma AB's own Interest Coverage has ranged from 0.49 to 443.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.82, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). EQL Pharma AB's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
40GF Score
Get the complete analysis for OSTO:EQL
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
